We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

149 hedge funds and large institutions have $342M invested in iShares US Pharmaceuticals ETF in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 44 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

7% more funds holding

Funds holding: 139149 (+10)

5% more capital invested

Capital invested by funds: $326M → $342M (+$16.8M)

0.52% less ownership

Funds ownership: 58.79%58.27% (-0.52%)

27% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 44

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $297K

Holders
149
Holders Change
+10
Holders Change %
+7.19%
% of All Funds
1.96%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
32
Reduced
44
Closed
7
Calls
Puts
$297K
Net Calls
-$297K
Net Calls Change
-$297K
Name Holding Trade Value Shares
Change
Change in
Stake
Fisher Asset Management
1
Fisher Asset Management
Washington
$209M -$6.23M -90,349 -3%
Morgan Stanley
2
Morgan Stanley
New York
$13.6M +$320K +4,645 +3%
Goldman Sachs
3
Goldman Sachs
New York
$10.6M +$503K +7,287 +5%
Bank of America
4
Bank of America
North Carolina
$8.32M -$480K -6,960 -6%
LPL Financial
5
LPL Financial
California
$8.24M -$295K -4,275 -4%
JP Morgan Chase
6
JP Morgan Chase
New York
$8.15M +$99.6K +1,443 +1%
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$7.5M -$888K -12,875 -11%
BNP Paribas Financial Markets
8
BNP Paribas Financial Markets
France
$7.26M -$6.9M -100,000 -50%
Brown Advisory
9
Brown Advisory
Maryland
$5.47M
Raymond James Financial
10
Raymond James Financial
Florida
$3.96M -$615K -8,920 -14%
CIC
11
Concord Investment Counsel
California
$3.75M +$3.57M +51,729 New
Wells Fargo
12
Wells Fargo
California
$2.95M -$264K -3,826 -9%
UBS Group
13
UBS Group
Switzerland
$2.45M -$528K -7,659 -18%
PGFC
14
Peapack-Gladstone Financial Corp
New Jersey
$2.34M -$42.4K -614 -2%
MFG
15
Merit Financial Group
Georgia
$2.27M
Commonwealth Equity Services
16
Commonwealth Equity Services
Massachusetts
$2.11M -$237K -3,431 -11%
Mariner
17
Mariner
Kansas
$1.92M -$2.28K -33 -0.1%
PP
18
Patten & Patten
Tennessee
$1.91M
Ameriprise
19
Ameriprise
Minnesota
$1.83M +$108K +1,563 +7%
GC
20
Grimes & Company
Massachusetts
$1.56M -$61.8K -896 -4%
CFA
21
Cahill Financial Advisors
Minnesota
$1.47M +$2.35K +34 +0.2%
Jones Financial Companies
22
Jones Financial Companies
Missouri
$1.36M -$577K -8,364 -30%
ST
23
Spinnaker Trust
Maine
$1.32M
BPA
24
Beacon Pointe Advisors
California
$1.28M -$158K -2,285 -11%
Bank of Montreal
25
Bank of Montreal
Ontario, Canada
$1.28M +$759K +11,006 +165%

IHE Hedge Fund Activity: Q3 2025 in Review

149 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2025, worth a combined $342M — up 5.2% from $326M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new IHE positions and 7 closed out — a net gain of 11 holders — while 32 added to existing stakes and 44 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $932K. The largest seller was BNP Paribas Financial Markets, cutting an estimated $6.9M.

  • 149 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2025, up from 139 in Q2 2025.
  • Funds reported $342M of iShares US Pharmaceuticals ETF stock for Q3 2025, up 5.2% quarter-over-quarter.
  • 18 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2025 and 7 closed out, a net change of +11 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2025 was Jane Street, an estimated $932K added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2025 was BNP Paribas Financial Markets, an estimated $6.9M sold.

Based on aggregated 13F filings for Q3 2025.